Kymera Therapeutics Inc
$ 65.99
2.68%
03 Dec - close price
- Market Cap 4,747,916,000 USD
- Current Price $ 65.99
- High / Low $ 66.51 / 64.26
- Stock P/E N/A
- Book Value 13.19
- EPS -3.60
- Next Earning Report 2026-02-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.19 %
- ROE -0.32 %
- 52 Week High 68.80
- 52 Week Low 19.45
About
Kymera Therapeutics Inc. is an innovative biopharmaceutical company headquartered in Watertown, Massachusetts, focused on transforming treatment paradigms through its proprietary protein degradation technology. By leveraging the body's inherent protein regulation systems, Kymera develops targeted small molecule therapies designed to selectively degrade disease-causing proteins related to cancer and autoimmune disorders. This unique therapeutic approach positions the company favorably within the biopharmaceutical sector, offering substantial growth potential for institutional investors as it progresses its robust pipeline toward clinical applications.
Analyst Target Price
$77.59
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-29 | 2025-08-11 | 2025-04-30 | 2025-02-20 | 2024-10-31 | 2024-08-07 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 | 2023-05-04 | 2023-02-23 |
| Reported EPS | -0.94 | -0.95 | -0.82 | -0.89 | -0.82 | -0.58 | -0.62 | -0.25 | -0.9 | -0.67 | -0.7 | -0.6 |
| Estimated EPS | -0.8613 | -0.83 | -0.73 | -0.7882 | -0.84 | -0.68 | -0.73 | -0.4 | -0.64 | -0.71 | -0.68 | -0.63 |
| Surprise | -0.0787 | -0.12 | -0.09 | -0.1018 | 0.02 | 0.1 | 0.11 | 0.15 | -0.26 | 0.04 | -0.02 | 0.03 |
| Surprise Percentage | -9.1374% | -14.4578% | -12.3288% | -12.9155% | 2.381% | 14.7059% | 15.0685% | 37.5% | -40.625% | 5.6338% | -2.9412% | 4.7619% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-19 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.8162 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: KYMR
2025-10-19 07:28:01
StockTradersDaily.com provides an AI-driven analysis of Kymera Therapeutics Inc. (NASDAQ: KYMR), detailing key findings, institutional trading strategies, and multi-timeframe signal analysis. The report highlights prevailing positive sentiment, identifies elevated downside risk, and offers specific entry, target, and stop-loss points for different trading approaches.
2025-10-15 11:51:30
Kymera Therapeutics Chief Medical Officer Jared Gollob sold 3,114 shares for $186,840 and exercised options for 1,473 shares. This transaction occurred as the stock neared its 52-week high, having gained over 135% in six months, with technical indicators suggesting it is in overbought territory. Analysts from Stifel, Truist Securities, H.C. Wainwright, Barclays, and RBC Capital have issued positive ratings and increased price targets for Kymera due to promising clinical data for its KT-621 program.
2025-10-14 21:37:34
This article reports that an application error occurred while loading the Investing.com India page, which was intended to display information about Kymera Therapeutics's Gollob selling $186k in shares. Due to the error, the specific details of the insider trading event are not available.
2025-10-14 21:14:00
Kymera Therapeutics's Chief Medical Officer, Jared Gollob, sold 3,114 shares of common stock for $186,840 and exercised options for an additional 1,473 shares. This sale occurred while the stock, NASDAQ:KYMR, was near its 52-week high, having gained over 135% in six months, with technical indicators suggesting it's in overbought territory. The company has also received several positive analyst updates and increased price targets based on its KT-621 program.
2025-10-14 17:52:17
Kymera Therapeutics, Inc. reached a new 52-week high of $60.00 on October 13, 2025, marking a 74.81% increase over the past year and outperforming the S&P 500. Despite its strong market performance, the company is currently operating at a loss, indicated by a negative price-to-earnings ratio and negative operating profit growth over the last five years. The article provides a detailed financial analysis, highlighting negative results in recent quarters and classifying the stock as "Risky" due to negative EBITDA.
2025-10-14 13:42:21
The article reports an application error encountered while trying to load content from Investing.com Canada related to Kymera Therapeutics director Albers selling shares worth $295,000. It indicates that a client-side exception prevented the display of the intended news.
